Prevention of meningococcal serogroup C disease by NeisVac-C™
- 1 March 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 8 (3) , 265-279
- https://doi.org/10.1586/14760584.8.3.265
Abstract
NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.Keywords
This publication has 51 references indexed in Scilit:
- Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United KingdomClinical and Vaccine Immunology, 2009
- Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational studyBMJ, 2008
- Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccinesArchives of Disease in Childhood, 2007
- No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndromeArchives of Disease in Childhood, 2007
- Immunogenicity, Reactogenicity, and Immune Memory after Primary Vaccination with a Novel Haemophilus influenzae - Neisseria meningitidis Serogroup C Conjugate VaccineClinical and Vaccine Immunology, 2007
- Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of ageArchives of Disease in Childhood, 2007
- Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trialBMJ, 2006
- Dynamic Models of Meningococcal Carriage, Disease, and the Impact of Serogroup C Conjugate VaccinationAmerican Journal of Epidemiology, 2005
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003
- Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naı̈ve controlsVaccine, 2001